Problemi speciali
Il bambino con eccesso di crescita tra variabilità clinica ed eterogeneità genetica
The child with overgrowth between clinical variability and genetic heterogeneity
Gregorio Serra, Mandy Schierz, Vincenzo Antona, Calogero Fabio Giardina*, Mario Giuffrè, Ettore Piro, Giovanni Corsello
Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”, Università di Palermo
*UOC di Neonatologia e Terapia Intensiva Neonatale, AO Ospedali Riuniti Villa Sofia-Cervello, Palermo
Aprile 2020 - pagg. 243 -248
Abstract
Either in the newborn or in the child overgrowth can be generalized or localized if it is limited to one or more body regions. When overgrowth depends on a metabolic imbalance, or it is constitutional, the excessive growth can be the only clinical sign. In most cases genomic or epigenetic alterations, which affect factors involved in cell proliferation and/or regulation of gene expression (observed also in tumours), are related to overgrowth syndromes, in which excess growth may be associated with dysmorphic features, neuromotor/intellectual disabilities and behavioural disorders. These rare conditions are characterized by clinical and molecular overlap. The paper describes the cases of three patients with localized overgrowth, in which a detailed evaluation of the phenotype, appropriately integrated by next generation sequencing (NGS) techniques, led to the genetic diagnosis of segmental overgrowth syndrome. Many patients with a previous clinical diagnosis of overgrowth syndrome are now framed in the context of segmental overgrowth syndromes associated with PIK3CA, whose identification may be obtained by extending molecular analyses to somatic cells. The paediatrician has to take into consideration these syndromes to guarantee an early genetic diagnosis and the appropriate clinical management to these patients (including reproductive counselling to the family, follow-up and oncological surveillance). NGS techniques improved the understanding of the molecular basis of some of these conditions, as well as the identification of the role of new genes and mechanisms, whose study may help to reduce the number of patients for which a genetic diagnosis related with the phenotype is not yet possible.
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Yachelevich N. Generalized overgrowth syndromes with prenatal onset. Curr Probl Pediatr Adolesc Health Care 2015;45(4):97-111.
2. Brioude F, Toutain A, Giabicani E, Cottereau E, Cormier-Daire V, Netchine I. Overgrowth syndromes - clinical and molecular aspects and tumour risk. Nat Rev Endocrinol 2019;15(5):299-311.
3. Kesavan K, Devaskar SU. Intrauterine growth restriction: postnatal monitoring and outcomes. Pediatr Clin North Am 2019;66(2):403-23.
4. Spittle AJ, Morgan C, Olsen JE, Novak I, Cheong JLY. Early diagnosis and treatment of cerebral palsy in children with a history of preterm birth. Clin Perinatol 2018;45(3):409-20.
5. Malhotra A, Allison BJ, Castillo-Melendez M, Jenkin G, Polglase GR, Miller SL. Neonatal morbidities of fetal growth restriction: pathophysiology and impact. Front Endocrinol (Lausanne) 2019;10:55.
6. Abi Habib W, Brioude F, Edouard T, et al. Genetic disruption of the oncogenic HMGA2-PLAG1-IGF2 pathway causes fetal growth restriction. Genet Med 2018;20(2):250-8.
7. Tatton-Brown K, Loveday C, Yost S, et al.; Childhood Overgrowth Collaboration. Mutations in epigenetic regulation genes are a major cause of overgrowth with intellectual disability. Am J Hum Genet 2017;100(5):725-36.
8. Busè M, Piccione M. Sindromi da iperaccrescimento e macrocrania. Prospettive in Pediatria 2019;49(193):129-38.
9. Kamien B, Ronan A, Poke G, et al. A clinical review of generalized overgrowth syndromes in the era of massively parallel sequencing. Mol Syndromol 2018;9(2):70-82.
10. Edmondson AC, Kalish JM. Overgrowth syndromes. J Pediatr Genet 2015;4(3):136-43.
11. Kalish JM, Biesecker LG, Brioude F, et al. Nomenclature and definition inasymmetric regional body overgrowth. Am J Med Genet A 2017;173(7):1735-8.
12. Graziani V, Dal Bo S, Sensi A, et al. Lo spettro delle manifestazioni legate alla mutazione del gene PTEN. Medico e Bambino 2017;36(5):303-8.
13. Keppler-Noreuil KM, Rios JJ, Parker VE, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 2015;167A(2):287-95.
14. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A 2014;164A(7): 1713-33.
15. Nathan N, Keppler-Noreuil KM, Biesecker LG, Moss J, Darling TN. Mosaic disorders of the PI3K/PTEN/AKT/TSC/mTORC1 signaling pathway. Dermatol Clin 2017;35(1):51-60.
16. Youssefian L, Vahidnezhad H, Baghdadi T, et al. Fibroadipose hyperplasia versus Proteus syndrome: segmental overgrowth with a mosaic mutation in the PIK3CA gene. J Invest Dermatol 2015;135(5):1450-3.
17. Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008;5(6):357-61.
18. Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011;365(7):611-9.
19. Mirzaa GM, Rivière JB, Dobyns WB. Megalencephaly sindrome and activating mutations in the PI3K-AKT pathway: MPPH and MCAP. Am J Med Genet C Semin Med Genet 2013;163C(2):122-30.
20. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27(41):5497-510.
21. Mirzaa G, Timms AE, Conti V, et al. PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight 2016;1(9).
22. Scott J, Cowell J, Robertson ME, et al. Insulin-like growth factor-II gene expression in Wilms’ tumour and embryonic tissues. Nature 1985;317(6034):260-2.
23. De Paoli A, Di Francesco A, Selicorni A. La sindrome di Beckwith-Wiedemann. Medico e Bambino 2019;38(8):509-20.
24. Graziani V, Mainetti M, Zucchini A, et al. Ipoglicemia neonatale, emipertrofia e macroglossia: quale diagnosi? Medico e Bambino 2015;34(1):44-9.
25. Gripp KW, Baker L, Kandula V, et al. Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation. Am J Med Genet A 2016;170(10):2559-69.
26. Kuentz P, St-Onge J, Duffourd Y, et al. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med 2017;19(9):989-97.